CNBC's Jim Cramer believes with the Democrats in control, Big Pharma will have a hard time growing with newer, high priced drugs. Their growth strategy will probably be more in the line of mergers and aquisitions. Abbott Laboratories (ABT) CEO Miles White has hinted in their last conference call that “it’s a good time to be a buyer, as long as there is a willing seller".
Of Cramer's potential four targets is Martek Bioscience (MATK), one of our local manufacturers. Given the current undervalued market, an M&A period like the mid 80's could happen again. Read his opinion at Mad Cap Recap .
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment